Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
Background Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers of type 2 inflammation. In the phase 3 LIBERTY ASTHMA QUEST trial (NCT02414854) in patients with uncontrolled, moderate-to-severe asthma, add-on dupilumab 2...
Main Authors: | , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
European Respiratory Society
2020-01-01
|
Series: | ERJ Open Research |
Online Access: | http://openres.ersjournals.com/content/6/1/00204-2019.full |